e-learning
resources
Glasgow 2004
Tuesday 07.09.2004
Lung fibrosis sarcoidosis alveolar microlithiasis and proteinosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Successful treatment by GMCSF of pulmonary alveolar proteinosis relapsing after a first GMCSF course
S. Boniface, F. Milhe, J. Y. Gaubert, M. Badier, B. Chetaille, M. Reynaud-Gaubert, A. Magnan (Marseilles, France)
Source:
Annual Congress 2004 - Lung fibrosis sarcoidosis alveolar microlithiasis and proteinosis
Session:
Lung fibrosis sarcoidosis alveolar microlithiasis and proteinosis
Session type:
Poster Discussion
Number:
4091
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Boniface, F. Milhe, J. Y. Gaubert, M. Badier, B. Chetaille, M. Reynaud-Gaubert, A. Magnan (Marseilles, France). Successful treatment by GMCSF of pulmonary alveolar proteinosis relapsing after a first GMCSF course. Eur Respir J 2004; 24: Suppl. 48, 4091
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Risk factors of adverse outcome after acute hospitalization in Idiopathic Pulmonary Fibrosis (IPF)
Lane-hamilton syndrome and CCF: a fatal association
Related content which might interest you:
Treatment of severe pulmonary alveolar proteinosis using inhaled GM-CSF
Source: Annual Congress 2010 - Rare diffuse lung diseases
Year: 2010
Rituximab therapy in autoimmune pulmonary alveolar proteinosis
Source: Eur Respir J 2009; 33: 1503-1506
Year: 2009
Inhaled GM-CSF for autoimune pulmonary alveolar proteinosis
Source: Short video statement 2020
Year: 2020
Treatment of pulmonary alveolar proteinosis (PAP) with administration of GM-CSF
Source: Eur Respir J 2002; 20: Suppl. 38, 447s
Year: 2002
Plasmapheresis for treatment of pulmonary alveolar proteinosis
Source: Eur Respir J 2009; 33: 1220-1222
Year: 2009
Pulmonary alveolar proteinosis: failure of treatment by bronchoscopic lobar lavages and GM-CSF treatment in a child
Source: Eur Respir J 2003; 22: Suppl. 45, 309s
Year: 2003
Reduced GM-CSF autoantibody in improved lung of autoimmune pulmonary alveolar proteinosis
Source: Eur Respir J 2012; 39: 777-780
Year: 2012
Pulmonary alveolar proteinosis
Source: Respipedia Article
Year: 2017
Neutralizing capacity of autoantibody against GM-CSF in patients with autoimmune pulmonary alveolar proteinosis
Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs)
Year: 2018
Granulocyte-macrophage colony stimulating factor inhalation therapy as a treatment for pulmonary alveolar proteinosis
Source: Eur Respir J 2003; 22: Suppl. 45, 377s
Year: 2003
Inhaled GM-CSF in pulmonary alveolar proteinosis (PAP) patient refractory to plasmapheresis combined with multiple whole lung lavages (WLL)
Source: International Congress 2016 – Orphan diseases I
Year: 2016
Aerosol granulocyte-macrophage colony-stimulating factor for pulmonary alveolar proteinosis
Source: Eur Respir J 2006; 27: 585-593
Year: 2006
An open-label trial of rituximab therapy in pulmonary alveolar proteinosis
Source: Eur Respir J 2011; 38: 1361-1367
Year: 2011
The effect of pentoxifylline on IL-12 and IL-18 release by alveolar macrophages in sarcoidosis and hypersensitivity pneumonitis versus idiopathic pulmonary fibrosis
Source: Eur Respir J 2003; 22: Suppl. 45, 377s
Year: 2003
CTGF and TNFa expression in alveolar macrophages of patients with idiopathic pulmonary fibrosis before and after treatment with azathioprine and interferon-g
Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms
Year: 2009
The analysis of alveolar macrophage form in secondary pulmonary alveolar proteinosis complicated with myelodysplastic syndrome.
Source: International Congress 2017 – Rare diseases
Year: 2017
Idiopathic pulmonary alveolar proteinosis: GM CSF therapy and whole lung lavage a case report
Source: Eur Respir J 2003; 22: Suppl. 45, 44s
Year: 2003
Autoimmune pulmonary alveolar proteinosis complicated with sarcoidosis: clinical courses and serum levels of anti-GM-CSF autoantibody
Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs)
Year: 2018
Inhalation therapy of interferon-gamma in patients with idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 266s
Year: 2005
Intercurrent intractable factors in autoimmune pulmonary alveolar proteinosis
Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept